![]()
11
| 4 | 2008
Klinisk Biokemi i Norden
Referenser
[1] Xu N, Dahlbäck B. A novel human apoli-
poprotein (apoM). J Biol Chem. 1999 Oct
29;274(44):31286-90.
[2] Faber K, Axler O, Dahlbäck B, Nielsen LB.
Characterization of apoM in normal and
genetically modified mice. J Lipid Res. 2004
Jul;45(7):1272-8.
[3] Axler O, Ahnström J, Dahlbäck B.
Apolipoprotein M associates to lipoproteins
through its retained signal peptide. FEBS
Lett. 2008 Mar 5;582(5):826-8.
[4] Christoffersen C, Ahnström J, Axler O,
Christensen EI, Dahlbäck B, Nielsen LB.
The signal peptide anchors apolipoprotein
M in plasma lipoproteins and prevents rapid
clearance of apolipoprotein M from plasma.
J Biol Chem. 2008 Jul 4;283(27):18765-72.
[5] Ahnström J, Faber K, Axler O, Dahlbäck
B. Hydrophobic ligand binding properties
of the human lipocalin apolipoprotein M. J
Lipid Res. 2007 Aug;48(8):1754-62.
[6] Duan J, Dahlbäck B, Villoutreix BO.
Proposed lipocalin fold for apolipoprotein
M based on bioinformatics and site-directed
mutagenesis. FEBS Lett. 2001 Jun 15;499(1-
2):127-32.
[7] Xu N, Hurtig M, Zhang XY, Ye Q, Nilsson-
Ehle P. Transforming growth factor-beta
down-regulates apolipoprotein M in HepG2
cells. Biochim Biophys Acta. 2004 Jul
5;1683(1-3):33-7.
[8] Feingold KR, Shigenaga JK, Chui LG, Moser
A, Khovidhunkit W, Grunfeld C. Infection
and inflammation decrease apolipopro-
tein M expression. Atherosclerosis. 2008
Jul;199(1):19-26.
[9] Richter S, Shih DQ, Pearson ER, Wolfrum
C, Fajans SS, Hattersley AT, et al. Regulation
of apolipoprotein M gene expression by
MODY3 gene hepatocyte nuclear factor-
1alpha: haploinsufficiency is associated with
reduced serum apolipoprotein M levels.
Diabetes. 2003 Dec;52(12):2989-95.
[10] Skupien J, Kepka G, Gorczynska-Kosiorz S,
Gebska A, Klupa T, Wanic K, et al. Evaluation
of Apolipoprotein M Serum Concentration
as a Biomarker of HNF-1alpha MODY. Rev
Diabet Stud. 2007 Winter;4(4):231-5.
[11] Cervin C, Axler O, Holmkvist J, Almgren P,
Rantala E, Tuomi T, et al. An investigation of
serum concentration of apoM as a MODY3
marker using a novel ELISA assay. 2008.
[12] Wolfrum C, Howell JJ, Ndungo E, Stoffel
M. Foxa2 activity increases plasma High
Density Lipoprotein levels by regulating
apolipoprotein M. J Biol Chem. 2008 June
13, 2008;283(24):16940-9.
[13] Axler O, Ahnström J, Dahlbäck B. An ELISA
for apolipoprotein M reveals a strong corre-
lation to total cholesterol in human plasma.
J Lipid Res. 2007 Aug;48(8):1772-80.
[14] Venteclef N, Haroniti A, Tousaint J-J,
Talianidis I, Delerive P. Regulation of
Anti-atherogenic Apolipoprotein M Gene
Expression by the Orphan Nuclear Receptor
LRH-1. J Biol Chem. 2008 February 15,
2008;283(7):3694-701.
[15] Christoffersen C, Jauhiainen M, Moser
M, Porse B, Ehnholm C, Boesl M, et al.
Effect of Apolipoprotein M on High Density
Lipoprotein Metabolism and Atherosclerosis
in Low Density Lipoprotein Receptor
Knock-out Mice. J Biol Chem. 2008 Jan
25;283(4):1839-47.
[16] Wolfrum C, Poy MN, Stoffel M.
Apolipoprotein M is required for prebeta-
HDL formation and cholesterol efflux to
HDL and protects against atherosclerosis.
Nat Med. 2005 Apr;11(4):418-22.
[17] Christoffersen C, Nielsen LB, Axler O,
Andersson A, Johnsen AH, Dahlbäck B.
Isolation and characterization of human
apolipoprotein M-containing lipoproteins. J
Lipid Res. 2006 Aug;47(8):1833-43.
[18] Ahnström J, Axler O, Jauhiainen M, Salomaa
V, Havulinna AS, Ehnholm C, et al. Levels of
apolipoprotein M are not associated with the
risk of coronary heart disease in two inde-
pendent case-control studies. J Lipid Res.
2008 Sep;49(9):1912-7.
